FEATURES OF PREECLAMPSIA COURSE AT IVF-INDUCED PREGNANCY: LITERARY REVIEW
Introduction: Preeclampsia, a multifactorial condition with a strong genetic influence, complicates pregnancy, childbirth, and the postpartum period, remaining a significant cause of maternal mortality. Despite modern diagnostic methods, screenings, and preventive measures, the incidence of preeclampsia remains unchanged. The increasing age of women planning pregnancy and the use of assisted reproductive technologies, such as IVF with donor oocytes, increase the risk of pregnancy complications.
This study aims to study the features of preeclampsia development in older women with IVF-induced pregnancies.
Search strategy: Both Russian and English articles, found in CyberLeninka, PubMed, Scopus, Google Scholar, and e-Library using keywords and medical headings from 2012 to 2024, were used. The review included 83 articles on the clinic, diagnosis, screening, and prevention of preeclampsia.
Results: Preeclampsia, a common complication of pregnancy, has a negative impact on the health of both the mother and the child. There is insufficient knowledge about the pathogenesis and prevention of this complication. The only effective treatment for preeclampsia is delivery; however, determining the optimal timing of delivery for the fetus presents a challenge, considering that prolonging pregnancy worsens the mother's condition. The duration of pregnancy directly increases the risk of lethal complications for the mother. Premature delivery, in turn, threatens the immaturity of the newborn's organs and systems, which can lead to vision, lung, and brain problems in the future. Early diagnosis and prevention of preeclampsia can significantly improve pregnancy outcomes for both the mother and the child.
Conclusion: Further research is needed to clarify the relationship between preeclampsia and chronic conditions during pregnancy. Early and reliable diagnostic markers for preeclampsia are required to initiate prevention and determine the optimal time for delivery. This, in turn, facilitates pathogenically justified preventive therapy from the early stages of pregnancy, reducing the economic burden of managing severe preeclampsia during pregnancy.
Keywords: preeclampsia, screening, preeclampsia diagnosis, in vitro fertilization (IVF), infertility.
Tatyana S. Slobodchikova1, https://orcid.org/0000-0003-2422-4722
Marina R. Izmailovich1*, https://orcid.org/0000-0001-8128-4356
Zhanna T. Amirbekova1, https://orcid.org/0000-0003-4254-1094
Dana Zh. Tayzhanova 1, https://orcid.org/0000-0001-6971-8764
Anna V. Skvortsova1, https://orcid.org/0000-0003-2200-2173
Dmitriy V. Vazenmiller1, https://orcid.org/0000-0003-4976-3992
Ramil T. Mustafin2, https://orcid.org/0000-0002-6454-3747
Kanan F. Tanriverdiev3, https://orcid.org/0009-0006-2659-4742
Zarina T. Shaikhina1, https://orcid.org/0009-0006-0717-139X
Агаева К.В. Проблема преэклампсии в современном акушерстве. Актуальні проблеми сучасної медицини: Вісник української медичної стоматологічної академії. 2018. №1 (61). С. 288-291.
2. Актаева Л.М., Мирзахметова Д.Д., Каусова Г.К. Перинатальные риски во время беременности в южных регионах Республики Казахстан. Вестник КазНМУ. 2019. № 1. С. 600-602.
3. Атабаева Х.Л. Основные принципы подготовки к беременности и ее ведение у беременных с преэклампсией на фоне выявленной тромбофилии. Акуш. Гинекол. Репрод. 2016. Т. 10. № 4. С. 30-38.
4. Всемирная организация здравоохранения (ВОЗ). Рекомендации ВОЗ по профилактике и лечению преэклампсии и эклампсии. Женева. 2014. 48 с.
5. Галина Т.В., Девятова Е.А., Гагаев Ч.Г. Преэклампсия: новые аспекты патогенеза, концепции скрининга и профилактики. Акуш. Гинекол.: Новости. Мнения. Обучения. 2017. №3 (17). С. 66-77.
6. Диагностика и лечение сердечно-сосудистых заболеваний при беременности. Российские рекомендации. Рос. Кардиол. Журн. 2013. №4. S1. 40 с.
7. Исенова С., Бодыков Г., Локшин В., Джусубалиева Т., Байкошкарова С., Карибаева Ш., Валиев Р., Кабыл Б. Особенности течения раннего неонатального периода новорожденных после применения ЭКО. Репрод. Мед. 2020. № 2 (43). С. 22-27.
8. Кудринских И.А., Белоцерковцева Л.Д., Мордовина И.И. Факторы риска, особенности течение беременности и исходы у пациенток с ранней преэклампсией при многоплодной и одноплодной беременности. Вестник СурГУ. Медицина. 2023. №2. С. 34-44.
9. Пицхелаури Е.Г., Стрижаков А.Н., Богачева Н.А., Кузьмина Т.Е., Федюнина И.А. Возможности прогнозирования развития преэклампсии с ранних сроков беременности у пациенток после вспомогательных репродуктивных технологий. Акуш. Гинекол. Репрод. 2019. №13(4). С. 305-312.
10. Пун Л.К., Шеннан А., Хайетт Дж.А. и др. Инициатива по преэклампсии Международной федерации гинекологии и акушерства (FIGO): практическое руководство по скринингу в I триместре и профилактике заболевания (адаптированная версия на русском языке под ред. З.С. Ходжаевой, Е.Л. Яроцкой, И.И. Баранова). Акуш. Гинекол.: Новости. Мнения. Обучения. 2019. №4 (26). С. 32-60.
11. Руденко Е.Е., Коган Е.А., Демура Т.А., Трифонова Н.С., Жарков Н.В. Особенности экспрессии HLA-DR в плаценте при развитии преэклампсии на фоне экстракорпорального оплодотворения с применением донорской яйцеклетки. Мед. Социол. Философ. Прикл. иссл. 2020. №1. С. 7-10.
12. Фетисова И.Н., Малышкина А.И., Панова И.А., Рокотянская Е.А., Фетисов Н.С., Ратникова С.Ю. Особенности генного контроля уровня артериального давления у пациенток с гипертензивными расстройствами при беременности. Науч. Рез. Биомед. Иссл. 2021. №7(1). С. 56-66.
13. Adu-Gyamfi E.A., Lamptey J., Duan F., Wang Y.X., Ding Y.B. The transforming growth factor β superfamily as possible biomarkers of preeclampsia: a comprehensive review. Biomark Med. 2019. N 13(15). P. 1321-1330.
14. Ahmadian E., Rahbar Saadat Y., Hosseiniyan Khatibi S.M. et al. Pre-Eclampsia: Microbiota possibly playing a role. Pharmacol Res. 2020. N 155. P. 104692.
15. Ahmed A., Ramma W. Unravelling the theories of pre-eclampsia: are the protective pathways the new paradigm? Br J Pharmacol. 2015. N 172(6). P. 1574-1586.
16. Aisagbonhi O., Morris G.P. Human Leukocyte Antigens in Pregnancy and Preeclampsia. Front Genet. 2022. N 13. P. 884275.
17. Akre S., Sharma K., Chakole S., Wanjari M.B. Eclampsia and Its Treatment Modalities: A Review Article. Cureus. 2022. N 14(9). P. e29080.
18. Alecsandru D., Barrio A., Garrido N., Aparicio P., Pellicer A., Moffett A., García-Velasco J.A. Parental human leukocyte antigen-C allotypes are predictive of live birth rate and risk of poor placentation in assisted reproductive treatment. Fertil. Steril. 2020. N 114. P. 809-817.
19. Alecsandru D., Garrido N., Vicario J.L., Barrio A., Aparicio P., Requena A., García-Velasco J.A. Maternal KIR haplotype influences live birth rate after double embryo transfer in IVF cycles in patients with recurrent miscarriages and implantation failure. Hum. Reprod. 2014. N 29. P. 2637-2643.
20. Almasi-Hashiani A., Omani-Samani R., Mohammadi M., et al. Assisted reproductive technology and the risk of preeclampsia: an updated systematic review and meta-analysis. BMC Pregnancy Childbirth. 2019. N 19(1). P. 149-162.
21. Berntsen S., Larsen E.C., la Cour Freiesleben N., Pinborg A. Pregnancy outcomes following oocyte donation. Best Pract Res Clin Obstet Gynaecol. 2021. Vol. 70. P. 81-91.
22. Blázquez A., García D., Rodríguez A., Vassena R., Figueras F., Vernaeve V. Is oocyte donation a risk factor for preeclampsia? A systematic review and meta-analysis. J. Assist. Reprod. Genet. 2016. Vol. 33 (7). P. 855-863.
23. Bos M., Baelde H.J., Bruijn J.A., Bloemenkamp K.V.M., van der Hoorn M.P., Turner R.J. Loss of placental thrombomodulin in oocyte donation pregnancies. Fertil. Steril. 2017. Vol. 107. P. 119-129.e5.
24. Cagino K., Bortoletto P., McCarter K., Forlenza K., Yau A., Thomas C., Melnick A.P., Prabhu M. Association between low fetal fraction and hypertensive disorders of pregnancy in in vitro fertilization-conceived pregnancies. Am. J. Obstet. Gynecol. 2021. Vol. 3 (6). P. 100463.
25. Chang K.J., Seow K.M., Chen K.H. Preeclampsia: Recent Advances in Predicting, Preventing, and Managing the Maternal and Fetal Life-Threatening Condition. Int. J. Environ. Res. Public Health. 2023. Vol. 20 (4). P. 2994.
26. Chen P., Hu K.L., Jin J. et al. Risk factors for twin pregnancy in women undergoing double cleavage embryo transfer // BMC Pregnancy Childbirth. 2022. Vol. 22. P. 264.
27. Chen Y.C., Lai Y.J., Su Y.T., Tsai N.C., Lan K.C. Higher gestational weight gain and lower serum estradiol levels are associated with increased risk of preeclampsia after in vitro fertilization. Pregn. Hypertens. 2020. Vol. 22. P. 126-131.
28. Chih H.J., Elias F.T.S., Gaudet L., Velez M.P. Assisted reproductive technology and hypertensive disorders of pregnancy: systematic review and meta-analyses. BMC Pregn. Childbirth. 2021. Vol. 21 (1). P. 449-469.
29. Conrad K.P. Evidence for Corpus Luteal and Endometrial Origins of Adverse Pregnancy Outcomes in Women Conceiving with or Without Assisted Reproduction. Obstet. Gynecol. Clin. North Am. 2020. Vol. 47 (1). P. 163-181.
30. Conrad K.P., Graham G.M., Chi Y.Y., et al. Potential influence of the corpus luteum on circulating reproductive and volume regulatory hormones, angiogenic and immunoregulatory factors in pregnant women. Am. J. Physiol. Endocrinol. Metab. 2019. Vol. 317 (4). P. E677-E685.
31. Conrad K.P., Rabaglino M.B., Post Uiterweer E.D. Emerging role for dysregulated decidualization in the genesis of preeclampsia. Placenta. 2017. Vol. 60. P. 119-129.
32. Conrad K.P., von Versen-Höynck F., Baker V.L. Risk of preeclampsia in artificial frozen embryo transfer as a result of insufficient corpus luteum hormone levels: a response. Am. J. Obstet. Gynecol. 2022. Vol. 227 (4). P. 676-677.
33. Dai F., Pan S., Lan Y., Tan H., Li J., Hua Y. Pregnancy outcomes and risk factors for preeclampsia in dichorionic twin pregnancies after in vitro fertilization: a five-year retrospective study. BMC Pregnancy Childbirth. 2022. Vol. 22 (1). P. 830-839.
34. Dior U.P., Laufer N., Chill H.H., et al. Increased incidence of preeclampsia in mothers of advanced age conceiving by oocyte donation. Arch. Gynecol. Obstet. 2018. Vol. 297 (5). P. 1293-1299.
35. Elenis E., Svanberg A.S., Lampic C., Skalkidou A., Åkerud H., Sydsjö G. Adverse obstetric outcomes in pregnancies resulting from oocyte donation: a retrospective cohort case study in Sweden. BMC Pregnancy Childbirth. 2015. Vol. 15. P. 247-256.
36. Epelboin S., Labrosse J., De Mouzon J., et al. Higher risk of pre-eclampsia and other vascular disorders with artificial cycle for frozen-thawed embryo transfer compared to ovulatory cycle or to fresh embryo transfer following in vitro fertilization. Front. Endocrinol. (Lausanne). 2023. Vol. 14. P. 1182148.
37. Erden M., Uyanik E., Demeestere I., Oktay K.H. Perinatal outcomes of pregnancies following autologous cryopreserved ovarian tissue transplantation: a systematic review with pooled analysis. Am. J. Obstet. Gynecol. Published online April 15, 2024.
38. Ervaala A., Laivuori H., Gissler M., Kere J., Kivinen K., Pouta A., Kajantie E., Heinonen S., Wedenoja S. Characteristics of preeclampsia in donor cell gestations. Pregnancy Hypertension. 2022. Vol. 27. P. 59-61.
39. Gekka Y., Adachi T., Oi R., Nakayama S., Kawana Y., Takeda Y., Nomura S., Ozaki A., Tanimoto T., Sakamoto H., Yamashita T. Hypertensive disorders of pregnancy by oocyte donation pregnancy in Japanese women aged 40 years or older: a single-center retrospective cohort study. Hypertens. Pregn. 2021. Vol. 40 (1). P. 36-44.
40. Ginstrom Ernstad E., Wennerholm U.-B., Khatibi A., et al. Neonatal and maternal outcome after frozen embryo transfer: Increased risks in programmed cycles // Am. J. Obstet. Gynecol. 2019. Vol. 221. P. 126.e1-18.
41. Guilbaud L., Santulli P., Studer E., Gayet V., Goffinet F., Le Ray C. Impact of oocyte donation on perinatal outcome in twin pregnancies. Fertil. Steril. 2017. Vol. 107 (4). P. 948-953.e1.
42. Hendin N., Meyer R., Peretz-Machluf R., Elbaz L., Maman E., Baum M. Higher incidence of preeclampsia among participants undergoing in-vitro fertilization after fewer sperm exposures. European Journal of Obstetrics, Gynecology, and Reproductive Biology. 2023. Vol. 285. P. 12-16.
43. Hiura H., Hattori H., Kobayashi N., et al. Genome-wide microRNA expression profiling in placentae from frozen-thawed blastocyst transfer. Clin. Epigenetics. 2017. Vol. 9. P. 79-91.
44. Hosseinzadeh P., Wild R.A., Hansen K.R. Diminished ovarian reserve: risk for preeclampsia in in vitro fertilization pregnancies. Fertil. Steril. 2023. Vol. 119 (5). P. 802-803.
45. Kenigsberg S., Bentov Y. Does contemporary ART lead to pre-eclampsia? A cohort study and meta-analysis. J. Assist. Reprod. Genet. 2021. Vol. 38. P. 651-659.
46. Keukens A., van Wely M., van der Meulen C., Mochtar M.H. Pre-eclampsia in pregnancies resulting from oocyte donation, natural conception or IVF: a systematic review and meta-analysis. Hum. Reprod. 2022. Vol. 37 (3). P. 586-599.
47. Kintiraki E., Papakatsika S., Kotronis G., Goulis D.G., Kotsis V. Pregnancy-induced hypertension. Hormones (Athens). 2015. Vol. 14. P. 211-223.
48. Lashley L.E., Buurma A., Swings G.M., Eikmans M., Anholts J.D., Bakker J.A., Claas F.H. Preeclampsia in autologous and oocyte donation pregnancy: is there a different pathophysiology? J. Reprod. Immunol. 2015. Vol. 109. P. 17-23.
49. Lee K., Brayboy K., Tripathi L. Pre-eclampsia: Scoping Review of Risk Factors and Suggestions for Future Research Direction. Regenerative Engineering and Translational Medicine. 2022. Vol. 8 (3). P. 394-406.
50. Luke B., Brown M.B., Eisenberg M.L., Callan C., Botting B.J., Pacey A., Sutcliffe A.G., Baker V.L. In vitro fertilization and risk for hypertensive disorders of pregnancy: associations with treatment parameters. Am. J. Obstet. Gynecol. 2020. Vol. 222 (4). P. 350-363.
51. Masoudian P., Nasr A., de Nanassy J., Fung-Kee-Fung K., Bainbridge S.A., El Demellawy D. Oocyte donation pregnancies and the risk of preeclampsia or gestational hypertension: a systematic review and meta-analysis. Am. J. Obstet. Gynecol. 2016. Vol. 214 (3). P. 328-339.
52. Meyer R., Orvieto R., Timerman Y., et al. Impact of the mode of conception on gestational hypertensive disorders at very advanced maternal age // Reprod. Biomed. Online. 2020. Vol. 40 (2). P. 281-286.
53. Monseur B.C., Morris J.R., Hipp H.S., Berghella V. Hypertensive disorders of pregnancy and infertility treatment: a population-based survey among United States women. J. Assist. Reprod. Genet. 2019. Vol. 36 (7). P. 1449-1456.
54. Moreno-Sepulveda J., Checa M.A. Risk of adverse perinatal outcomes after oocyte donation: a systematic review and meta-analysis. J. Assist. Reprod. Genet. 2019. Vol. 36 (10). P. 2017-2037.
55. Moreno-Sepulveda J., Espinós J.J., Checa M.A. Lower risk of adverse perinatal outcomes in natural versus artificial frozen-thawed embryo transfer cycles: a systematic review and meta-analysis. Reprod. Biomed. Online. 2021. Vol. 42 (6). P. 1131-1145.
56. Okun N., Sierra S. Genetics committee; special contributors. Pregnancy outcomes after assisted human reproduction. J. Obstet. Gynaecol. Can. 2014. Vol. 36 (1). P. 64-83.
57. Omani-Samani R., Alizadeh A., Almasi-Hashiani A., Mohammadi M., Maroufizadeh S., Navid B., Khedmati Morasae E., Amini P. Risk of preeclampsia following assisted reproductive technology: systematic review and meta-analysis of 72 cohort studies. J. Matern. Fetal Neonatal Med. 2020. Vol. 33 (16). Р. 2826-2840.
58. Opdahl S., Henningsen A.A., Tiitinen A., et al. Risk of hypertensive disorders in pregnancies following assisted reproductive technology: a cohort study from the CoNARTaS group. Hum. Reprod. 2015. Vol. 30 (7). P. 1724-1731.
59. Papúchová H., Meissner T.B., Li Q., Strominger J.L., Tilburgs T. The Dual Role of HLA-C in Tolerance and Immunity at the Maternal-Fetal Interface. Front. Immunol. 2019. Vol. 10. P. 2730.
60. Pereira M.M., Mainigi M., Strauss J.F. Secretory products of the corpus luteum and preeclampsia. Hum. Reprod. Update. 2021. Vol. 27 (4). P. 651-672.
61. Resta S., Scandella G., Mappa I., Pietrolucci M.E., Maqina P., Rizzo G. Placental Volume and Uterine Artery Doppler in Pregnancy Following In Vitro Fertilization: A Comprehensive Literature Review // Journal of Clinical Medicine. 2022. Vol. 11 (19). P. 5793.
62. Roberts J.M., Escudero C. The placenta in preeclampsia. Pregnancy Hypertens. 2012. Vol. 2 (2). P. 72-83.
63. Roque M., Valle M., Sampaio M., Geber S. Obstetric outcomes after fresh versus frozen-thawed embryo transfers: A systematic review and meta-analysis. JBRA Assist. Reprod. 2018. Vol. 22 (3). P. 253-260.
64. Saito S., Nakabayashi Y., Nakashima A., Shima T., Yoshino O. A new era in reproductive medicine: Consequences of third-party oocyte donation for maternal and fetal health. Semin. Immunopathol. 2016. Vol. 38. P. 687-697.
65. Simopoulou M., Sfakianoudis K., Maziotis E., Grigoriadis S., Giannelou P., Rapani A., Tsioulou P., Pantou A., et al. The Impact of Autoantibodies on IVF Treatment and Outcome: A Systematic Review. Int. J. Mol. Sci. 2019. Vol. 20. P. 892-915.
66. Schonkeren D., Swings G., Roberts D., Claas F., de Heer E., Scherjon S. Pregnancy close to the edge: An immunosuppressive infiltrate in the chorionic plate of placentas from uncomplicated egg cell donation. PLoS ONE. 2012. Vol. 7. P. e32347.
67. Schwarze J.E., Borda P., Vásquez P., Ortega C., Villa S., Crosby J.A., Pommer R. Is the risk of preeclampsia higher in donor oocyte pregnancies? A systematic review and meta-analysis. JBRA Assist. Reprod. 2018. Vol. 22 (1). P. 15-19.
68. Sibai B. Subfertility/infertility and assisted reproductive conception are independent risk factors for pre-eclampsia // BJOG. 2015. Vol. 122 (7). P. 923.
69. Silvestris E., Petracca E.A., Mongelli M., et al. Pregnancy by Oocyte Donation: Reviewing Fetal-Maternal Risks and Complications. Int. J. Mol. Sci. 2023. Vol. 24 (18). P. 13945.
70. Singh N., Malhotra N., Mahey R., Saini M., Patel G., Sethi A. Comparing maternal outcomes in spontaneous singleton pregnancies versus in vitro fertilization conception: Single-center 10-year cohort study // JBRA Assist. Reprod. 2022. Vol. 26 (4). P. 583-588.
71. Storgaard M., Loft A., Bergh C., et al. Obstetric and neonatal complications in pregnancies conceived after oocyte donation: a systematic review and meta-analysis. BJOG. 2017. Vol. 124 (4). P. 561-572.
72. Thomopoulos C., Salamalekis G., Kintis K., et al. Risk of hypertensive disorders in pregnancy following assisted reproductive technology: overview and meta-analysis. J. Clin. Hypertens. (Greenwich). 2017. Vol. 19 (2). P. 173-183.
73. Turner R.J., Bloemenkamp K.W., Bruijn J.A., Baelde H.J. Loss of Thrombomodulin in Placental Dysfunction in Preeclampsia. Arterioscler. Thromb. Vasc. Biol. 2016. Vol. 36. P. 728-735.
74. Umesawa M., Kobashi G. Epidemiology of hypertensive disorders in pregnancy: prevalence, risk factors, predictors and prognosis. Hypertens. Res. 2017. Vol. 40 (3). P. 213-220.
75. van Aanhold C.C.L., Bos M., Mirabito Colafella K.M., et al. Thrombomodulin is upregulated in the kidneys of women with pre-eclampsia. Sci. Rep. 2021. Vol. 11 (1). P. 5692.
76. van Bentem K., Bos M., van der Keur C., Brand-Schaaf S.H., Haasnoot G.W., Roelen D.L., Eikmans M., Heidt S., Claas F.H.J., Lashley E.E.L.O., et al. The development of preeclampsia in oocyte donation pregnancies is related to the number of fetal-maternal HLA class II mismatches. J. Reprod. Immunol. 2020. Vol. 137. P. 103074.
77. von Versen-Höynck F., Häckl S., Selamet Tierney E.S., Conrad K.P., Baker V.L., Winn V.D. Maternal Vascular Health in Pregnancy and Postpartum After Assisted Reproduction. Hypertension. 2020. Vol. 75 (2). P. 549-560.
78. von Versen-Höynck F., Schaub A.M., Chi Y.Y., Chiu K.H., Liu J., Lingis M., Stan Williams R., Rhoton-Vlasak A., Nichols W.W., Fleischmann R.R., Zhang W., Winn V.D., Segal M.S., Conrad K.P., Baker V.L. Increased Preeclampsia Risk and Reduced Aortic Compliance With In Vitro Fertilization Cycles in the Absence of a Corpus Luteum. Hypertension. 2019. Vol. 73 (3). P. 640-649.
79. Wang L., Cheng L., Zhang S., Su M., Jin Y., Luo D. Mediation effect of pregnancy-induced hypertension on the association between assisted reproductive technology and adverse neonatal outcomes: a population-based study. BMC Pregnancy Childbirth. 2023. Vol. 23 (1). P. 385.
80. Woo I., Hindoyan R., Landay M., et al. Perinatal outcomes after natural conception versus in vitro fertilization (IVF) in gestational surrogates: a model to evaluate IVF treatment versus maternal effects. Fertil. Steril. 2017. Vol. 108 (6). P. 993-998.
81. Zaat T., Zagers M., Mol F., Goddijn M., van Wely M., Mastenbroek S. Fresh versus frozen embryo transfers in assisted reproduction. Cochrane Database Syst. Rev. 2021. Vol. 2 (2). P. CD011184.
82. Zhang J. Risk of preeclampsia in artificial cycles of frozen embryo transfer in vitro fertilization pregnancies: a response. Am. J. Obstet. Gynecol. 2021. Vol. 225 (4). P. 467-468.
83. Zhang N., Tan J., Yang H., Khalil R.A. Comparative risks and predictors of preeclamptic pregnancy in the Eastern, Western and developing world. Biochem. Pharmacol. 2020. Vol. 182. P. 114247.
Number of Views: 179
Bibliography link
Slobodchikova T.S., Izmailovich M.R., Amirbekova J.T., Tayzhanova D.Zh., Skvortsova A.V., Vazenmiller D.V., Mustafin R.T., Tanriverdiev K.F., Shaikhina Z.T. Features of preeclampsia course at IVF-induced pregnancy: literary review // Nauka i Zdravookhranenie [Science & Healthcare]. 2024. Vol.26 (3), pp. 158-185. doi 10.34689/SH.2024.26.3.020Related publications:
CHARACTERISTICS OF THE INTESTINAL MICROBIOME IN STROKE PATIENTS WITH INSULIN RESISTANCE
REACTIVE ARTHRITIS IN THE CONTEXT OF CONNECTIVE TISSUE DYSPLASIA – THE ROLE OF THE ORGANISM'S MICROBIOME
EMBOLIZATION OF THE UTERINE ARTERIES FOR LATE POSTPARTUM HEMORRHAGE DUE TO METROENDOMETRITIS: A CLINICAL CASE
DESCRIPTION OF A CLINICAL CASE OF GENERALIZED LYMPHADENOPATHY OF UNKNOWN ETIOLOGY
CLINICAL RELEVANCE OF KRAS MUTATION TESTING IN METASTATIC COLORECTAL USING DIFFERENT SEQUENCING PLATFORMS: A CASE REPORT